Plain-English translation of NCT07321106 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called that works by activating your own immune cells to attack colorectal cancer. Researchers are studying how safe this treatment is, how your body processes it, and whether it can help shrink tumors. The trial is designed for patients whose cancer has advanced and has not responded well to previous treatments.
Many patients with a specific type of colorectal cancer (called microsatellite stable) do not respond well to existing therapies, and their options become very limited as the disease progresses. This medication represents a new approach by recruiting the body's own immune system to fight the cancer, which has shown promise in other cancer types.
You likely qualify if…
You likely don't qualify if…
You would receive escalating doses of the medication, with researchers carefully monitoring how your body tolerates each dose level before increasing it. You would have regular clinic visits for blood tests, imaging scans, and physical exams to assess how the treatment is working and any side effects you experience. The exact duration and visit schedule depend on which dose level you are assigned to and how your cancer responds.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
United States